Two patents awarded to Methylgene in oncology segment

Methylgene is a biopharmaceutical company and mainly concentratinf in development in oncology sector.
Recently USPTO has awarded grant of two composition of matter patents to Methylgene for its multi-targeted kinase inhibitor (MGCD265) which is specifically for cancer treatment.
MGCD265 is still in clinical trial phase and will be available in market once all clinical trials completes with positive results and regulatory approval is received.
Source (Pharmabiz)